Gastrointestinal stromal tumors: classification, diagnosis, and treatment

Vashakmadze L.A.; Kolobaev I.V.; Bespalov P.D.; Stepanov S.O.; Kekeeva T.V.

doi:https://doi.org/

Vashakmadze L.A.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava RF

Kolobaev I.V.

Hertsen Moscow Oncology Research Center, Moscow, Russia

Bespalov P.D.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

Stepanov S.O.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

Kekeeva T.V.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

Gastrointestinal stromal tumors: classification, diagnosis, and treatment

Authors:

Vashakmadze L.A., Kolobaev I.V., Bespalov P.D., Stepanov S.O., Kekeeva T.V.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2013;2(2): 66‑70

Read: 13188 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Vashakmadze LA, Kolobaev IV, Bespalov PD, Stepanov SO, Kekeeva TV. Gastrointestinal stromal tumors: classification, diagnosis, and treatment. P.A. Herzen Journal of Oncology. 2013;2(2):66‑70. (In Russ.)

Подписка 2026 Онкология. Журнал им. П.А. Герцена (P.A. Herzen Journal of Oncology)

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Clinical and morphological characteristics of intraductal carcinoma in situ of the mammary gland. P.A. Herzen Journal of Oncology. 2025;(6):83-87

Diagnostic capabilities of multipoint transthoracic biopsy under ultrasound navigation of mediastinal formations. P.A. Herzen Journal of Oncology. 2026;(1):24-29

Gastrointestinal stromal tumors of the esophagus in adults: a systematic review. Russian Journal of Evidence-Based Gastroenterology. 2025;(1):5-28

Evaluation of VEGF-A, SP-D and MUC-1 expression in poisoning with baclofen and its combination with ethanol. Forensic Medical Expertise. 2025;(2):45-49

Pulmonary arterial hypertension in disorders of porto-caval hemodynamics. The role of ultrasound diagnostics. Russian Cardiology Bulletin. 2025;(1):90-98

Morphological and immunohistochemical characteristics of skin specimens after isolated and combined injections of poly-L-lactic acid and hyaluronic acid. Plastic Surgery and Aesthetic Medicine. 2025;(3):50-62

Diaphragmatic relaxation masquerading as COPD. Pirogov Russian Journal of Surgery. 2025;(10-2):107-113

Abstract:

Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the gastrointestinal tract. The wide introduction of molecular diagnosis and the advent of targeted therapy drugs considerably changed treatment approaches and disease prognosis in patients with GIST. The review presents data on the history of the issue, on the definition of main concepts, different instrumental and laboratory diagnostic methods, and treatment options.

Keywords:

gastrointestinal stromal tumor

glivec

ultrasound diagnosis

immunohistochemical study

Authors:

Vashakmadze L.A.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava RF

Kolobaev I.V.

Hertsen Moscow Oncology Research Center, Moscow, Russia

Bespalov P.D.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

Stepanov S.O.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

Kekeeva T.V.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

Close metadata

References:

Joensuu N., Roberts P.J., Sarlomo-Rikala M., Andersson L.C., Tervahartiala P., Tuveson D. et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N. Engl. J. Med. 2001; 344: 1052-6.
Stilidi I.S., Nikulin M.P. Gastrointestinal'nye stromal'nye opukholi. http://onco-med.ru/specialization/stomach/article03/
Corless C.L., Fletcher J.A., Heinrich M.C. Biology of gastrointestinal stromal tumors. J. Clin. Oncol. 2004; 22: 3813-25.
Gold J.S., Dematteo R.P. Neoadjuvant therapy for gastrointestinal stromal tumor (GIST): racing against resistance. Ann. Surg. Oncol. 2007; 14 (4): 1247-8.
Medvedeva B.M., Luk'yanchenko A.B. KT-proyavleniya gastrointestinal'nykh stromal'nykh opukholei. Vestnik Moskovskogo onkologicheskogo obshchestva. 2005; 11: 3a-4.
Mazur M., Clarke H. Gastric stromal tumors. Reappraisal of histogenesis. Am. J. Surg. Pathol. 1983; 7 (6): 507-19.
Heinrich M.C., Corless C.L., Demetri G.D. et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 2003; 21: 434-9.
Hirota S., Isozaki K., Moriyama Y. et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998; 279: 577-80.
Kekeeva T.V., Zavalishina L.E., Andreeva Yu.Yu., Kolobaev I.V., Butenko A.V., Frank G.A. Analiz mutatsii gena KIT pri gastrointestinal'nykh stromal'nykh opukholyakh. Rossiiskii onkologicheskii zhurnal. 2009; 5: 23-8.
Heinrich M.C., Corless C.L., Duensing A. et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003; 299: 708-10.
Singer S., Rubin B.P., Lux M.L. et al. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J. Clin. Oncol. 2002; 20: 3898-905.
Demetri G.D., Benjamin R.S., Blanke C.D. et al. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)-update of the NCCN clinical practice guidelines. J. Natl. Compr. Canc. Netw. 2007; 5 (Suppl. 2): S1-29.
Blackstein M.E., Blay J.Y., Corless C. et al. Gastrointestinal stromal tumours: consensus statement on diagnosis and treatment. Can. J. Gastroenterol. 2006; 20: 157-63.
Casali P.G., Jost L., Reichardt P., Schlemmer M., Blay J.Y.; ESMO Guidelines Working Group. Gastrointestinal stromal tumours: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol. 2009; 20 (Suppl. 4): 64-7.
National Comprehensive Cancer Network. Clinical practice guidelines in oncology for soft tissue sarcoma. Version 2. Fort Washington, Pa: National Comprehensive Cancer Network; 2009.
Hassan I., You Y.N., Shyyan R. et al. Surgically managed gastrointestinal stromal tumors: a comparative and prognostic analysis. Ann. Surg. Oncol. 2008; 15: 52-9.
DeMatteo R.P. et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann. Surg. 2000; 231: 51-8.
Ng E.H. et al. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann. Surg. 1992; 215: 68-77.
Eisenberg B.L., Judson I. Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy. Ann. Surg. Oncol. 2004; 11 (5): 465-75.
Heinrich M.C., Blanke C.D., Druker B.J., Corless C.L. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J. Clin. Oncol. 2002; 20: 1692-703.
Heinrich M., Corless C., Blanke C., Demetri G., Joensuu H., Mehren M. et al. KIT mutational status predicts clinical response to STI571 in patients with metastatic gastrointestinal stromal tumors (GISTs), Proceedings of ASCO. 2002; 21: 2a; abstr.6.
Demetri G.D., von Mehren M., Blanke C.D. et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 2002; 347: 472-80.
Blanke C.D., Demetri G.D., von Mehren M. et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J. Clin. Oncol. 2008; 26: 620-5.
Blanke C.D., Rankin C., Demetri G.D. et al. Phase III randomized, intergroup trial assessing imatinib mesylate at 2 dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J. Clin. Oncol. 2008; 26: 626-32.
Verweij J., Casali P.G., Zalcberg J. et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004; 364: 1127-34.
Casali P., Verweij J., Kotasek D. et al. Imatinib mesylate in advanced gastrointestinal stromal tumors (GIST): survival analysis of the intergroup EORTC/ISG/AGITG randomized trial in 946 patients. Eur. J. Cancer. 2005; 3 (suppl): 201; abstr. 711.
Van Glabbeke M.M., Owzar K., Rankin C., Simes J., Crowley J.; GIST Meta-Analysis Group (MetaGIST). Comparison of 2 doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): a meta analysis based on 1640 patients (pts) [abstract]. J. Clin. Oncol. 2007; 25 (18, Suppl.): abstr. 10004.
Demetri G.D., van Oosterom A.T., Garrett C.R. et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomized controlled trial. Lancet. 2006; 368: 1329-38.
Hopkins T.G., Marples M., Stark D. Sunitinib in the management of gastrointestinal stromal tumours (GISTs). Eur. J. Surg. Oncol. 2008; 34: 844-50.
Rock E.P., Goodman V., Jiang J.X. et al. Food and drug administration drug approval summary: sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist. 2007; 12: 107-13.
Dematteo R.P., Ballman K.V., Antonescu C.R. et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009; 373: 1097-104.
Dematteo R.P., Owzar K., Antonescu C.R. et al. Efficacy of adjuvant imatinib mesylate following complete resection of localized, primary gastrointestinal stromal tumor (GIST) at high risk of recurrence: the U.S. Intergroup phase II trial ACOSOG Z9000 [abstract]. In: Paper presented at: 2008 Gastrointestinal Cancers Symposium; January 25-27, 2008, Orlando, Fla. 2008: abstr. 8.
Zhan W.H.; China Gastrointestinal Cooperative Group. Efficacy and safety of adjuvant post-surgical therapy with imatinib in patients with high risk of relapsing GIST [abstract]. J. Clin. Oncol. 2007; 25 (18, Suppl): abstr. 10045.
Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum. Pathol. 2008; 39 (10): 1411.
Dematteo R.P., Gold J.S., Saran L., Gönen M., Liau K.H., Maki R.G. et al. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer. 2008; 112 (3): 608-15.
European Organisation for Research and Treatment of Cancer. EORTC 62024 study protocol. Phase III randomized study of adjuvant imatinib mesylate versus observation only in patients with completely resected localized gastrointestinal stromal tumor at intermediate- or high-risk of relapse. http://www.cancer.gov/clinicaltrials/EORTC-62024. Accessed September 2, 2009.
Scandinavian Sarcoma Group. SSGXVIII/AIO study protocol. Study comparing 12 months versus 36 months of imatinib in the treatment of gastrointestinal stromal tumor (GIST). http://clinicaltrials.gov/ct2/show/NCT00116935?intr=%22Imatinib%22&rank=1. Accessed September 2, 2009.
Andtbacka R.H., Ng C.S., Scaife C.L. et al. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann. Surg. Oncol. 2007; 14: 14-24.
Bonvalot S., Eldweny H., Péchoux C.L., Vanel D., Terrier P., Cavalcanti A. et al. Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era. Ann. Surg. Oncol. 2006; 13 (12): 1596-603.